4//SEC Filing
Jordan Erica 4
Accession 0001479290-24-000074
CIK 0001479290other
Filed
Apr 16, 8:00 PM ET
Accepted
Apr 17, 4:34 PM ET
Size
5.6 KB
Accession
0001479290-24-000074
Insider Transaction Report
Form 4
Jordan Erica
Chief Commercial Officer
Transactions
- Sale
Common Stock
2024-04-16$3.80/sh−2,392$9,096→ 114,864 total
Footnotes (2)
- [F1]Represents the number of shares required to be sold by the Reporting Person, to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") granted on April 3, 2023 which vest in equal installments over a four year period. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F2]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0002012846
Filing Metadata
- Form type
- 4
- Filed
- Apr 16, 8:00 PM ET
- Accepted
- Apr 17, 4:34 PM ET
- Size
- 5.6 KB